{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:49:33Z","timestamp":1761238173982,"version":"3.41.2"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.pharep.2015.02.008","type":"journal-article","created":{"date-parts":[[2015,3,4]],"date-time":"2015-03-04T10:33:54Z","timestamp":1425465234000},"page":"928-933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Partial effects of the AMPAkine CX717 in a strain specific battery of tests for manic-like behavior in black Swiss mice"],"prefix":"10.1007","volume":"67","author":[{"given":"Nirit Z.","family":"Kara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shlomit","family":"Flaisher-Grinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-5541","authenticated-orcid":false,"given":"Haim","family":"Einat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"1","key":"10.1016\/j.pharep.2015.02.008_bib0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.nurx.2005.12.009","article-title":"Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets","volume":"3","author":"Carlson","year":"2006","journal-title":"NeuroRx"},{"issue":"4","key":"10.1016\/j.pharep.2015.02.008_bib0320","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.pbb.2011.09.010","article-title":"Novel glutamatergic agents for major depressive disorder and bipolar disorder","volume":"100","author":"Machado-Vieira","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"issue":"29","key":"10.1016\/j.pharep.2015.02.008_bib0325","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1523\/JNEUROSCI.1258-04.2004","article-title":"Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression","volume":"24","author":"Du","year":"2004","journal-title":"J Neurosci"},{"issue":"12","key":"10.1016\/j.pharep.2015.02.008_bib0330","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1523\/JNEUROSCI.20-12-04480.2000","article-title":"Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo","volume":"20","author":"Snyder","year":"2000","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.pharep.2015.02.008_bib0335","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1523\/JNEUROSCI.3080-07.2008","article-title":"The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior","volume":"28","author":"Du","year":"2008","journal-title":"J Neurosci"},{"issue":"9","key":"10.1016\/j.pharep.2015.02.008_bib0340","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/sj.npp.1301312","article-title":"Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders","volume":"32","author":"Beneyto","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pharep.2015.02.008_bib0345","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.neubiorev.2008.10.001","article-title":"Neurobiological evidence for thalamic, hippocampal and related glutamatergic abnormalities in bipolar disorder: a review and synthesis","volume":"33","author":"Ng","year":"2009","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"10.1016\/j.pharep.2015.02.008_bib0350","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/187152707780363258","article-title":"AMPA receptors in the therapeutic management of depression","volume":"6","author":"Bleakman","year":"2007","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"Suppl.","key":"10.1016\/j.pharep.2015.02.008_bib0355","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1111\/j.1440-1819.1998.tb03224.x","article-title":"Brain imaging of affective disorders and schizophrenia","volume":"52","author":"Kishimoto","year":"1998","journal-title":"Psychiatry Clin Neurosci"},{"issue":"5","key":"10.1016\/j.pharep.2015.02.008_bib0360","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1399-5618.2012.01028.x","article-title":"Antibodies to the glutamate receptor in mania","volume":"14","author":"Dickerson","year":"2012","journal-title":"Bipolar Disord"},{"issue":"4","key":"10.1016\/j.pharep.2015.02.008_bib0365","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0006-3223(99)00159-6","article-title":"Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study","volume":"47","author":"Auer","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharep.2015.02.008_bib0370","first-page":"1101","article-title":"Novel glutamatergic drugs for the treatment of mood disorders","volume":"9","author":"Lapidus","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"10.1016\/j.pharep.2015.02.008_bib0375","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0361-9230(01)00523-8","article-title":"Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder","volume":"55","author":"Meador-Woodruff","year":"2001","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.pharep.2015.02.008_bib0380","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1196\/annals.1300.016","article-title":"Glutamate and depression: clinical and preclinical studies","volume":"1003","author":"Paul","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"10.1016\/j.pharep.2015.02.008_bib0385","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1111\/j.1460-9568.2007.05560.x","article-title":"Acute stress-mediated increases in extracellular glutamate levels in the rat amygdala: differential effects of antidepressant treatment","volume":"25","author":"Reznikov","year":"2007","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharep.2015.02.008_bib0390","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuroscience.2013.04.031","article-title":"Involvement of pGluR1, EAAT2 and EAAT3 in offspring depression induced by prenatal stress","volume":"250","author":"Zhang","year":"2013","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.pharep.2015.02.008_bib0395","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0893-133X(01)00370-0","article-title":"Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder","volume":"26","author":"McCullumsmith","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharep.2015.02.008_bib0400","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1196\/annals.1300.036","article-title":"Lithium regulates total and synaptic expression of the AMPA glutamate receptor GluR2 in vitro and in vivo","volume":"1003","author":"Gray","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.pharep.2015.02.008_bib0405","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.neuropharm.2007.11.002","article-title":"Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test","volume":"54","author":"Gould","year":"2008","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pharep.2015.02.008_bib0410","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0896-6273(03)00195-8","article-title":"Finding the intracellular signaling pathways affected by mood disorder treatments","volume":"38","author":"Coyle","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.pharep.2015.02.008_bib0415","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1196\/annals.1300.031","article-title":"Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression","volume":"1003","author":"Du","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pharep.2015.02.008_bib0420","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-6606-7-5","article-title":"A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia","volume":"7","author":"Kubota-Sakashita","year":"2014","journal-title":"Mol Brain"},{"issue":"1","key":"10.1016\/j.pharep.2015.02.008_bib0425","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coph.2005.09.005","article-title":"Glutamate-based therapeutic approaches: ampakines","volume":"6","author":"Lynch","year":"2006","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"10.1016\/j.pharep.2015.02.008_bib0430","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2174\/138945007780618490","article-title":"Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior","volume":"8","author":"Arai","year":"2007","journal-title":"Curr Drug Targets"},{"issue":"13","key":"10.1016\/j.pharep.2015.02.008_bib0435","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1097\/00001756-199609020-00031","article-title":"Effect of the AMPA receptor modulator IDRA 21 on LTP in hippocampal slices","volume":"7","author":"Arai","year":"1996","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/j.pharep.2015.02.008_bib0440","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0306-4522(03)00423-8","article-title":"Ampakines reduce methamphetamine-driven rotation and activate neocortex in a regionally selective fashion","volume":"121","author":"Hess","year":"2003","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pharep.2015.02.008_bib0445","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002130050386","article-title":"A profile of the behavioral changes produced by facilitation of AMPA-type glutamate receptors","volume":"133","author":"Davis","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.pharep.2015.02.008_bib0450","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0006-8993(96)01049-9","article-title":"Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats","volume":"738","author":"Larson","year":"1996","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.pharep.2015.02.008_bib0455","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0022-3565(24)38148-0","article-title":"Synergistic interactions between ampakines and antipsychotic drugs","volume":"289","author":"Johnson","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"10.1016\/j.pharep.2015.02.008_bib0460","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0028-3908(00)00194-5","article-title":"Antidepressant-like actions of an AMPA receptor potentiator (LY392098)","volume":"40","author":"Li","year":"2001","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pharep.2015.02.008_bib0465","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/A:1023648923447","article-title":"Enhancement of antidepressant potency by a potentiator of AMPA receptors","volume":"23","author":"Li","year":"2003","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.pharep.2015.02.008_bib0470","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.neuropharm.2012.07.013","article-title":"AMPAKINE enhancement of social interaction in the BTBR mouse model of autism","volume":"64","author":"Silverman","year":"2013","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharep.2015.02.008_bib0475","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1124\/jpet.103.053694","article-title":"Chronic elevation of brain-derived neurotrophic factor by ampakines","volume":"307","author":"Lauterborn","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pharep.2015.02.008_bib0480","first-page":"1","article-title":"Black Swiss mice as a new animal model for mania: a preliminary study","volume":"1","author":"Hiscock","year":"2007","journal-title":"J Med Biol Sci"},{"issue":"1","key":"10.1016\/j.pharep.2015.02.008_bib0485","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jneumeth.2008.09.018","article-title":"Attenuation of high sweet solution preference by mood stabilizers: a possible mouse model for the increased reward-seeking domain of mania","volume":"177","author":"Flaisher-Grinberg","year":"2009","journal-title":"J Neurosci Methods"},{"issue":"3","key":"10.1016\/j.pharep.2015.02.008_bib0490","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.vascn.2009.03.003","article-title":"A possible utilization of the mice forced swim test for modeling manic-like increase in vigor and goal-directed behavior","volume":"59","author":"Flaisher-Grinberg","year":"2009","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"1","key":"10.1016\/j.pharep.2015.02.008_bib0495","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbr.2011.04.047","article-title":"Modeling mania: further validation for black swiss mice as model animals","volume":"223","author":"Hannah-Poquette","year":"2011","journal-title":"Behav Brain Res"},{"issue":"Article 10","key":"10.1016\/j.pharep.2015.02.008_bib0500","first-page":"1","article-title":"Strain specific battery of tests for separate behavioral domains of mania","volume":"1","author":"Flaisher-Grinberg","year":"2010","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.pharep.2015.02.008_bib0505","first-page":"1","article-title":"Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK-3) inhibitors in a strain specific model of acute mania","volume":"6","author":"Kalinichev","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharep.2015.02.008_bib0510","doi-asserted-by":"crossref","DOI":"10.1097\/FBP.0000000000000128","article-title":"The effects of the atypical antipsychotic asenapine in a strain-specific battery of tests for mania-like behaviors","author":"Ene","year":"2015","journal-title":"Behav Pharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2015.02.008_bib0515","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.pharep.2014.03.013","article-title":"Partial effects of the protein kinase C inhibitor chelerythrine in a battery of tests for manic-like behavior in black Swiss mice","volume":"66","author":"Einat","year":"2014","journal-title":"Pharmacol Rep"},{"issue":"11","key":"10.1016\/j.pharep.2015.02.008_bib0520","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2174\/1389450110607011399","article-title":"Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders","volume":"7","author":"Gould","year":"2006","journal-title":"Curr Drug Targets"},{"issue":"8","key":"10.1016\/j.pharep.2015.02.008_bib0525","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2174\/156720511798192709","article-title":"Effects of the putative cognitive-enhancing ampakine, CX717, on attention and object recognition memory","volume":"8","author":"Zheng","year":"2011","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"10.1016\/j.pharep.2015.02.008_bib0530","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1073\/pnas.91.2.777","article-title":"Facilitation of glutamate receptors enhances memory","volume":"91","author":"Staubli","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.pharep.2015.02.008_bib0535","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1371\/journal.pbio.0030299","article-title":"Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates","volume":"3","author":"Porrino","year":"2005","journal-title":"PLoS Biol"},{"issue":"1","key":"10.1016\/j.pharep.2015.02.008_bib0540","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-2999(02)01338-9","article-title":"Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model","volume":"440","author":"Knapp","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.pharep.2015.02.008_bib0545","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1073\/pnas.0811228106","article-title":"Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice","volume":"106","author":"Simmons","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharep.2015.02.008_bib0550","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/ilar.47.2.124","article-title":"Behavioral phenotyping of transgenic and knockout mice: practical concerns and potential pitfalls","volume":"47","author":"Bailey","year":"2006","journal-title":"ILAR J"},{"key":"10.1016\/j.pharep.2015.02.008_bib0555","series-title":"Current Protocols in Neuroscience","article-title":"Behavioral neuroscience","author":"Crawley","year":"2007"},{"issue":"1","key":"10.1016\/j.pharep.2015.02.008_bib0560","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s10519-006-9093-4","article-title":"Establishment of a battery of simple models for facets of bipolar disorder: a practical approach to achieve increased validity, better screening and possible insights into endophenotypes of disease","volume":"37","author":"Einat","year":"2007","journal-title":"Behav Genet"},{"issue":"9","key":"10.1016\/j.pharep.2015.02.008_bib0565","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd1825","article-title":"The ascent of mouse: advances in modelling human depression and anxiety","volume":"4","author":"Cryan","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"5\u20136","key":"10.1016\/j.pharep.2015.02.008_bib0570","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/FBP.0b013e3282ee2aa8","article-title":"The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior","volume":"18","author":"Schmidt","year":"2007","journal-title":"Behav Pharmacol"},{"issue":"5","key":"10.1016\/j.pharep.2015.02.008_bib0575","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrd2462","article-title":"Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders","volume":"7","author":"Sanacora","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.pharep.2015.02.008_bib0580","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/MN:32:2:173","article-title":"Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics","volume":"32","author":"Bachmann","year":"2005","journal-title":"Mol Neurobiol"},{"issue":"2","key":"10.1016\/j.pharep.2015.02.008_bib0585","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FBP.0b013e32834f9e4e","article-title":"Behavioral differences in black Swiss mice from separate colonies: implications for modeling domains of mania","volume":"23","author":"Juetten","year":"2012","journal-title":"Behav Pharmacol"},{"issue":"3\u20134","key":"10.1016\/j.pharep.2015.02.008_bib0590","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.physbeh.2011.03.005","article-title":"Behavioral and pharmacological assessment of a potential new mouse model for mania","volume":"103","author":"Scotti","year":"2011","journal-title":"Physiol Behav"},{"issue":"Suppl. 1","key":"10.1016\/j.pharep.2015.02.008_bib0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00406-012-0323-x","article-title":"Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry","volume":"262","author":"Fountoulakis","year":"2012","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.pharep.2015.02.008_bib0600","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002130050165","article-title":"Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice","volume":"129","author":"Gleason","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.pharep.2015.02.008_bib0605","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/syn.890150409","article-title":"A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task","volume":"15","author":"Granger","year":"1993","journal-title":"Synapse"},{"issue":"8","key":"10.1016\/j.pharep.2015.02.008_bib0610","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/0269881111405353","article-title":"Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep","volume":"26","author":"Boyle","year":"2012","journal-title":"J Psychopharmacol"},{"year":"2007","series-title":"Kaplan and Sadock's Synopsis of Psychiatry","author":"Sadock","key":"10.1016\/j.pharep.2015.02.008_bib0615"},{"issue":"3","key":"10.1016\/j.pharep.2015.02.008_bib0620","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-2999(78)90414-4","article-title":"\u201cBehavioural despair\u201d in rats and mice: strain differences and the effects of imipramine","volume":"51","author":"Porsolt","year":"1978","journal-title":"Eur J Pharmacol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114015000377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114015000377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:35:58Z","timestamp":1752611758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2015.02.008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1734114015000377"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2015.02.008","relation":{},"ISSN":["1734-1140"],"issn-type":[{"type":"print","value":"1734-1140"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Partial effects of the AMPAkine CX717 in a strain specific battery of tests for manic-like behavior in black Swiss mice","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2015.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}